Challenges in defining healthspan
The concept of healthspan is relatively new in geroscience research, which seeks to understand the biological mechanisms of aging (Burch et al. 2014; Sierra and Kohanski 2017) . Prior to the year 2000, only 14 papers were indexed on PubMed with Bhealthspan^or Bhealth span^in the title or abstract. By mid-2018, that number has grown to more than 900 (Fig. 1) . Notably, several of these use the exact phrases Bincreases healthspan,^Bimproves healthspan,^or Bextends healthspan,^implying that healthspan is a quantifiable phenotype. In contrast, a recent discussion session at the 2018 Nathan Shock Center Summit and American Aging Association Annual Meeting entitled BHow healthy is the healthspan concept?^indicates that there are no accepted or validated metrics for measuring healthspan. How then are claims of increased healthspan so routinely making it into the peer-reviewed literature? A widespread lack of clarity and precision in the use and meaning of this term among both authors and reviewers is evident, and this author will somewhat shamefacedly admit to being among the offenders (Bitto et al. 2016; Leiser et al. 2011; Sutphin et al. 2012; Urfer et al. 2017) .
It is perhaps useful to begin by asking Bwhat is the definition of healthspan?^. While it is unlikely everyone would agree on a single definition, one common definition is that healthspan is the period of life spent in good health, free from the chronic diseases and disabilities of aging. This definition implies that healthspan is a length of chronological time beginning at birth and ending at some subsequent time when an individual is no longer in good health and/or is suffering from diseases or disabilities of aging. Conceptually, this is a nice definition, as it allows us to consider healthspan as a quantitative continuous variable, in the same way that we consider lifespan. This would, in principle, be useful for determining how different genes, environmental parameters, or interventions impact healthspan in a quantitative way. It would also allow us to measure the relative impact of such factors on healthspan compared to their impact on lifespan. This is important, since some interventions have been suggested to increase healthspan without increasing lifespan, and such interventions would have clinical utility if they had similar health benefits in people. Similarly, it is at least theoretically possible that other interventions could increase lifespan without increasing healthspan to a proportional or greater extent, which is something we clearly do not want to do in people.
It is immediately apparent, however, that there are some significant problems with this definition of healthspan. First, Bgood health^is subjective. Two different people with the same medical condition may perceive their health quite differently. Additionally, Bgood health^may also be reversible, with some individuals going through multiple periods of poor health interspersed with good health. It is also unclear how many diseases and/or disabilities an individual must have to reach the end of their healthspan. Is one disease enough? Are all diseases equal in this regard? Finally, it is not the case that only diseases of aging cause loss of good health. There are many severe childhood disorders, for example, that result in sufficiently poor health that they would likely constitute an end of that individual's healthspan by any reasonable definition.
One major flaw with the current healthspan concept is that health is not a binary trait with only two states: good and bad. Instead, health itself may be better considered as a continuous variable that changes in a dynamic way throughout life. The health trajectory will be different in different individuals, but will generally trend downward with age. In principle, a Bhealthspan indexŵ hich quantifies overall health could be developed, perhaps akin to established frailty indices (Kane et al. 2017; Kim et al. 2017; Mitnitski et al. 2017) or geropathology platforms (Snider et al. 2018) , but more inclusive of other aspects of health (e.g. emotional, psychological, etc.). With such a tool, it would certainly be possible to arbitrarily define a value below which healthspan is considered to be over if a discreet chronological measure of healthspan is required. More informative perhaps would be to consider the area under the healthspan curve over a given time period or throughout life, in order to obtain a single Bhealthspan metric^for each individual (Fig. 2) . Such a metric would allow for rigorous, statistically valid comparisons of geroscience interventions to determine their impact on healthspan.
When and where to use the term BhealthspanÛ ntil such time as a comprehensive healthspan metric is adopted, it would seem prudent to refrain from using the term Bhealthspan^in the scientific literature, except as a conceptual construct. While this may seem an extreme position, a reasoned argument can be made that the status quo is detrimental, sowing confusion within the field and perhaps giving the impression that geroscience is less rigorous than other fields of scientific research.
Particularly problematic are studies that measure only one or two age-related phenotypes and make claims regarding healthspan in general. It was recently suggested that an Boverall assessment of health in several domains across several ages^should be required to justify claims that an intervention increases healthspan (Richardson et al. 2016) ; however, this recommendation does not address the fundamental problems outlined above. Even in cases where an intervention appears to broadly delay age-related declines and improve functional measures of aging Bin several domains and across several ages^, such as rapamycin treatment in mice Johnson et al. 2015) , there is no method available to assess whether healthspan is extended in a statistically valid manner. Indeed, imprecise definitions of healthspan have likely contributed to controversies related to rapamycin in mice (Johnson et al. 2013; Neff et al. 2013; Richardson 2013 ) and mutation of the insulin-like receptor DAF-2 in C. elegans (Bansal et al. 2015; Ewald et al. 2018; Hahm et al. 2015) . Given the current inability to quantify healthspan at all, these would seem to be counterproductive debates with potentially negative impact on how the field is perceived. The concept of healthspan has proven to be quite useful, on the other hand, for popularizing geroscience among the broader scientific and lay communities. It is a concept that is easy to understand and is more palatable to a general audience than increasing lifespan. Indeed, while some would debate the ethics of research aimed at increasing lifespan (Pijnenburg and Leget 2007) , there is broad agreement that expanding the period of life spent in good health is a worthwhile research endeavor, with significant economic and social benefits (Goldman et al. 2013; Nikolich-Zugich et al. 2016 ). As such, the concept of improving healthspan should continue to be an outward-facing point of emphasis for geroscience in the future.
